A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy As First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study